New model, new drugs, and a ‚remarkable‘ response in adrenal cancer

Two new studies use new models to identify genetic targets and test promising treatments in adrenal cancer. One patient was treated with the immunotherapy pembrolizumab and now more than a year after starting treatment remains on the drug with 77 percent tumor reduction and no new metastases. (Mehr in: Cancer News — ScienceDaily)